The company, in its regulatory filing, said it (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients.
On Thursday, Zydus Cadila launched the cheapest generic version of Gilead Sciences’ antiviral drug remdesivir in India to treat Covid-19. Amid the reports of shortages of the drug at hospitals in the world’s third worst-hit country, Zydus has decided to price it at ₹ 2,800 ($37.44) per 100mg vial.
The company, in its regulatory filing, said it (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients.
A few weeks ago, officials in some Indian states had complained of the supply issue. But earlier this week, a top executive at drugmaker Cipla said the supplies were stabilizing.
Zydus became the fifth pharmaceutical company to launch a copy of the antiviral in India after privately held Hetero Labs, Cipla, Mylan NV, and Jubilant Life Sciences.
Coronavirus cases continue to rise rapidly across the country, with India reporting its biggest single-day spike in new Covid-19 cases.
67,000 cases of coronavirus infection were recorded in a matter of 24 hours, taking the total tally to 23.9 lakh in the world’s third-worst infected country, according to the Health Ministry’s data this morning. Over 16.9 lakh patients have recovered while over 47,000 deaths have been recorded since the beginning of the pandemic.
Wednesday was a sixth consecutive day that India reported over 60,000 cases of coronavirus.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
